Gastrointestinal complications of oncologic therapy

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 5, Issue 12, 2008, Pages 682-696

  Davila, Marta ^a   Bresalier, Robert S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANIDULAFUNGIN; ANTINEOPLASTIC AGENT; ATROPINE PLUS DIPHENOXYLATE; CAPECITABINE; CASPOFUNGIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FAMCICLOVIR; FLUCONAZOLE; FLUOROURACIL; FOLINIC ACID; FOSCARNET; GANCICLOVIR; IRINOTECAN; ITRACONAZOLE; LOPERAMIDE; METHOTREXATE; MICAFUNGIN; OCTREOTIDE; OXALIPLATIN; SORAFENIB; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR; VORICONAZOLE;

CANCER THERAPY; CANDIDA ALBICANS; CANDIDIASIS; CONSTIPATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG DOSE TITRATION; DRUG FEVER; ESOPHAGITIS; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX VIRUS; LIVER HYPERPLASIA; LIVER INJURY; LIVER NODULAR REGENERATIVE HYPERPLASIA; LIVER TOXICITY; LIVER VASCULAR INJURY; MALIGNANT NEOPLASTIC DISEASE; MYCOSIS; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; STEATOSIS; STEM CELL TRANSPLANTATION; VIRUS INFECTION; VOMITING;

ANTINEOPLASTIC AGENTS; CONSTIPATION; DIARRHEA; ENTEROCOLITIS, NEUTROPENIC; ESOPHAGITIS; GRAFT VS HOST DISEASE; HUMANS; PROCTITIS; RADIATION INJURIES;

EID: 57049159806     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep1277     Document Type: Review

References (125)

1. Benson CA et al. (2004) Treating opportunistic infections among HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/ Infectious Disease Society of America. MMWR Recomm Rep 53: 1-112
2. McDonald GB et al. (1985) Esophageal infections in immunosuppressed patients after marrow transplantation. Gastroenterology 88: 1111-1117
3. Pappas PG et al. (2004) Guidelines for the treatment of candidiasis. Clin Infect Dis 38: 161-189
4. Wilcox CM et al. (1997) A randomized, double-blind comparison of Itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 176: 227-232
5. Ally R et al. (2001) A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 33: 1447-1454
6. Perfect JR et al. (2003) Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36 1122-1131
7. Villanueva A et al. (2002) A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 113: 294-299
8. De Wet N et al. (2004) A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 39: 842-849
9. Krause DS et al. (2004) A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 39: 770-775
10. Baehr PH and McDonald GB (1994) Esophageal infections: Risk factors, presentation, diagnosis, and treatment. Gastroenterology 106 509-532
11. McBane RD and Gross JB Jr (1991) Herpes esophagitis: Clinical syndrome, endoscopic appearance, and diagnosis in 23 patients. Gastrointest Endosc 37: 600-603
12. Reed EC et al. (1990) Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial. Ann Intern Med 112: 505-510
13. Blanshard C et al. (1995) Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: A randomized comparison. J Infect Dis 172: 622-628
14. Whitley RJ et al. (1998) Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: Recommendations of an international panel. Arch Intern Med 158: 957-969
15. Biron KK (2006) Antiviral drugs for cytomegalovirus diseases. Antiviral Res 71: 154-163
16. Maguire PD et al. (1999) Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys 45: 97-103
17. Choy H et al. (1999) Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semin Radiat Oncol 9: 90-96
18. Repici A et al. (2004) Temporary placement of an expandable polyester silicone-covered stent for treatment of refractory benign esophageal strictures. Gastrointest Endosc 60: 513-519
19. Evrard S et al. (2004) Self-expanding plastic stents for benign esophageal lesions. Gastrointest Endosc 60: 894-900
20. Fuchs CS et al. (2003) Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21: 807-814
21. Raijman I et al. (1998) Palliation of malignant dysphagia and fistulae with coated expandable metal esophageal stents: Experience with 101 patients. Gastrointest Endosc 48: 172-179
22. National Cancer Institute Common Toxicity Criteria [http://www.ctep.cancer.gov/forms/CTCAEv3.pdf/]
23. Sloan JA et al. (2002) Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 20: 1491-1498
24. Cascinu S et al. (1997) Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) study. Support Care Cancer 5: 314-317
25. Abigerges D et al. (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13: 210-221
26. Saltz LB et al. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914
27. Sargent DJ et al. (2001) Recommendation for caution with irinotecan, fluorouracil and leucovorin for colorectal cancer. N Engl J Med 345: 144-145
28. Rothenberg ML et al. (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 19: 3801-3807
29. Haller DG et al. (2008) Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 26: 2118-2123
30. Kuebler JP et al. (2007) Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-Fluorouracil/Leucovorin plus or minus Oxaliplatin. Cancer 110 1945-1950
31. Delaunoit T et al. (2004) Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin. Cancer 101: 2170-2176
32. Perez-Soler R et al. (2004) Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J Clin Oncol 22: 3238-3247
33. Strumberg D et al. (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four Phase I trials in patients with advanced refractory solid tumors. Oncologist 12: 426-437
34. Lenz HJ et al. (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24 4914-4921
35. O'Connell MJ et al. (1994) Improving adjuvant therapy for rectal cancer by combining protracted infusion-fluorouracil with radiation therapy after curative surgery. N Engl J Med 331: 502-507
36. Abigerges D et al. (1994) Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86: 446-449
37. Benson AB et al. (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22: 2918-2926
38. Wadler S et al. (1995) Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea. J Clin Oncol 13: 222-226
39. Barbounis V et al. (2001) Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Support Care Cancer 9 258-260
40. Kelly CP et al. (1994) Clostridium difficile colitis. N Engl J Med 330: 257-262
41. Anand A and Glatt AE (1993) Clostridium difficile infection associated with antineoplastic chemotherapy: A review. Clin Infect Dis 17: 109-113
42. Doern GV et al. (1992) Laboratory diagnosis of Clostridium difficile-associated gastrointestinal disease: Comparison of a monoclonal antibody enzyme immunoassay for toxins A and B with a monoclonal antibody enzyme immunoassay for toxin A only and two cytotoxicity assays. J Clin Microbiol 30: 2042-2046
43. Gerding DN et al. (1995) Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 16: 459-477
44. Knapp CC et al. (1993) Comparison of vidas Clostridium difficile toxin-A assay and premier C. difficile toxin-A assay to cytotoxin-B tissue culture assay for the detection of toxins of C. difficile. Diagn Microbiol Infect Dis 17: 7-12
45. Bartlett JG (2002) Antibiotic-associated diarrhea. N Engl J Med 346: 334-349
46. Apisarnthanarak A et al. (2002) Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: Case series and review of the literature. Clin Infect Dis 35: 690-696
47. Urbach DR and Rotstein OD (1999) Typhlitis. Can J Surg 42: 415-419
48. Tedesco FJ et al. (1985) Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 80: 867-868
49. Katz JA et al. (1990) Typhlitis. An 18-year experience and postmortem review. Cancer 65: 1041-1047
50. Gorschlüter M et al. (2005) Neutropenic enterocolitis in adults: Systematic analysis of evidence quality. Eur J Haematol 75: 1-13
51. Sloas MM et al. (1993) Typhlitis in children with cancer: A 30-year experience. Clin Infect Dis 17: 484-490
52. Wade DS et al. (1992) Neutropenic enterocolitis. Clinical diagnosis and treatment. Cancer 69: 17-23
53. Kouroussis C et al. (2000) Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: A report of five cases. Am J Clin Oncol 23: 309-313
54. Shamberger RC et al. (1986) The medical and surgical management of typhlitis in children with acute nonlymphocytic (myelogenous) leukemia. Cancer 57: 603-609
55. Anderson H et al. (1987) VAD chemotherapy - toxicity and efficacy - in patients with multiple myeloma and other lymphoid malignancies. Hematol Oncol 5: 213-222
56. Singhal S et al. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565-1571
57. Brandt LJ et al. (2005) Systematic review of the management of chronic constipation in North America. Am J Gastroenterol 100 S5-S21
58. Schwartz JM et al. (2001) Severe gastrointestinal bleeding after hematopoietic cell transplantation, 1987-1997: Incidence, causes and outcome. Am J Gastroenterol 96: 385-393
59. Weisdorf DJ et al. (1990) Acute upper gastrointestinal graft-versus-host disease: Clinical significance and response to immunosuppressive therapy. Blood 76: 624-629
60. Snover DC et al. (1985) A histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. Hum Pathol 16: 387-392
61. Sviland L et al. (1988) Histologic features of skin and rectal biopsy specimens after autologous and allogeneic bone marrow transplantation. J Clin Pathol 41: 48-54
62. Cox GJ et al. (1994) Etiology and outcome of diarrhea after marrow transplantation: A prospective study. Gastroenterology 107: 1398-1407
63. Terdiman JP et al. (1996) The role of endoscopic evaluation in patients with suspected intestinal graft-versus-host disease after allogeneic bone-marrow transplantation. Endoscopy 28: 680-685
64. Daneshpouy M et al. (2002) Activated eosinophils in upper gastrointestinal tract of patients with graft-versus-host disease. Blood 99: 3033-3040
65. Carlens S et al. (1998) Risk factors for chronic graft-versus-host disease after bone marrow transplantation: A retrospective single centre analysis. Bone Marrow Transplant 22: 755
66. Atkinson K (1990) Chronic graft-versus-host disease. Bone Marrow Transplant 5: 69-82
67. Akpek G et al. (2003) Gastrointestinal involvement in chronic graft-versus-host disease: A clinicopathologic study. Biol Blood Marrow Transplant 9: 46-51
68. Shulman HM et al. (1988) A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation. Hepatology 8: 463-470
69. Snover DC et al. (1984) Hepatic graft versus host disease: A study of the predictive value of liver biopsy in diagnosis. Hepatology 4: 123-130
70. Babb RR (1996) Radiation proctitis: A review. Am J Gastroenterol 91: 1309-1311
71. Keeffe EB et al. (2006) A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: An update. Clin Gastroenterol Hepatol 4: 936-962
72. Stockdale AD and Biswas A (1997) Long-term control of radiation proctitis following treatment with sucralfate enemas. Br J Surg 84: 379
73. Sasai T et al. (1998) Treatment of chronic post-radiation proctitis with oral administration of sucralfate. Am J Gastroenterol 93: 1593-1595
74. Mayer R et al. (2001) Hyperbaric oxygen - an effective tool to treat radiation morbidity in prostate cancer. Radiother Oncol 61: 151-156
75. Al-Sabbagh R et al. (1996) Evaluation of short-chain fatty acid enemas: Treatment of radiation proctitis. Am J Gastroenterol 91 1814-1816
76. Biswal BM et al. (1995) Intrarectal formalin application, an effective treatment for grade III haemorrhagic radiation proctitis. Radiother Oncol 35: 212-215
77. Fantin AC et al. (1999) Argon beam coagulation for treatment of symptomatic radiation-induced proctitis. Gastrointest Endosc 49 515-518
78. Tjandra JJ and Sengupta S (2001) Argon plasma coagulation is an effective treatment for refractory hemorrhagic radiation proctitis. Dis Colon Rectum 44: 1759-1765
79. Taieb S et al. (2001) Effective use of argon plasma coagulation in the treatment of severe radiation proctitis. Dis Colon Rectum 44: 1766-1771
80. Silva RA et al. (1999) Argon plasma coagulation therapy for hemorrhagic radiation proctosigmoiditis. Gastrointest Endosc 50 221-224
81. Lucarotti ME et al. (1991) Surgical management of intestinal radiation injury. Dis Colon Rectum 34: 865-869
82. Lok AS et al. (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100: 182-188
83. Liang R et al. (1999) Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: A review of the problem. J Clin Oncol 17: 394-398
84. Aksoy S et al. (2007) Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 48: 1307-1312
85. Yeo W et al. (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 62: 299-307
86. Yeo W et al. (2004) Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90: 1306-1311
87. Yeo W et al. (2004) Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 22: 927-934
88. Kawatani T et al. (2001) Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 67: 45-50
89. Lee WM (1995) Drug induced hepatotoxicity. N Engl J Med 333: 1118-1127
90. Goldberg JW and Lidsky MD (1985) Cyclophosphamide-associated hepatotoxicity. South Med J 78: 222-223
91. George CB et al. (1984) Hepatic dysfunction and jaundice following high-dose cytosine arabinoside. Cancer 54: 2360-2362
92. Moertel CG et al. (1993) Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol 11 2386-2390
93. Hohn D et al. (1989) A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group trial. J Clin Oncol 7: 1646-1654
94. Kemeny N et al. (1987) Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 107: 459-465
95. Chang AE et al. (1987) A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206: 685-693
96. Shorey J et al. (1968) Hepatotoxicity of mercaptopurine. Arch Intern Med 122: 54-58
97. Romagnuolo J et al. (1998) Cholestatic hepatocellular injury with azathioprine: A case report and review of the mechanisms of hepatotoxicity. Can J Gastroenterol 12: 479-483
98. Berkowitz RS et al. (1986) Ten year's experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. Gynecol Oncol 23: 111-118
99. Roenigk HH et al. (1982) Methotrexate guidelines: Revised. J Am Acad Dermatol 6: 145-155
100. Johnson PJ et al. (1992) Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: Relation to liver tests and pharmacokinetic parameters. Br J Cancer 65: 751-755
101. Fernandez FG et al. (2005) Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200: 845-853
102. Rubbia-Brandt L et al. (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15: 460-466
103. Vauthey JN et al. (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24: 2065-2072
104. Hubert C et al. (2007) Nodular regenerative hyperplasia: A deleterious consequence of chemotherapy for colorectal liver metastases? Liver Int 27: 938-943
105. Erichsen C and Jonsson PE (1984) Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma. J Surg Oncol 27: 268-270
106. Stoneham S et al. (2003) Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia. Br J Haematol 123: 100-102
107. Read AE et al. (1986) Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy. Ann Intern Med 104: 651-655
108. Sterneck M et al. (1991) Azathioprine hepatotoxicity after liver transplantation. Hepatology 14: 806-810
109. Rollins BJ (1986) Hepatic veno-occlusive disease. Am J Med 81 297-306
110. Vassal G et al. (1990) Busulfan and veno-occlusive disease of the liver. Ann Intern Med 112: 881
111. Joensuu H et al. (1986) Fatal necrosis of the liver during ABVD chemotherapy for Hodgkin's disease. A case report. Cancer 58 1437-1440
112. Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358: 2482-2494
113. Gordon MS and Cunningham D (2005) Managing patients treated with bevacizumab combination therapy. Oncology 69: 25-33
114. Hurwitz H et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342
115. Badgwell BD et al. (2008) Management of bevacizumab-associated bowel perforation: A case series and review of the literature. Ann Oncol 19: 577-582
116. Sugrue M et al. (2006) Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol 24: 154s
117. Runzi M and Layer P (1996) Drug-associated pancreatitis: Facts and fiction. Pancreas 13: 100-109
118. McArthur KE (1996) Review article: Drug-induced pancreatitis. Aliment Pharmacol Ther 10: 23-28
119. Glueck CJ et al. (1994) Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemia women. J Lab Clin Med 123: 59-64
120. Hozumi Y et al. (1998) Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab 83: 1633-1635
121. Kawanishi H et al. (1973) Azathioprine-induced acute pancreatitis. N Engl J Med 289: 357
122. Izraeli S et al. (1994) Acute pancreatitis after ifosfamide therapy. Cancer 74: 1627-1628
123. Mallory A and Kern F (1980) Drug-induced pancreatitis: A critical review. Gastroenterology 78: 813-820
124. Siemers RF et al. (1985) High-dose cytosine arabinoside-associated pancreatitis. Cancer 56: 1940-1942
125. Beaven AW and Shea TC (2007) The effect of palifermin on chemotherapy and radiation-induced mucositis:a review of the current literature. Support Cancer Ther 4: 188-197